Blog | BioInformant

Gradalis® Announces Initiation of Phase 3 Study of Vigil(TM) in Ewing’s sarcoma

August 28, 2018 By Cade Hildreth, Founder & President Leave a Comment

– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study –
– The trial will use product produced from Gradalis’ recently-upgraded cGMP Carrollton facility –

DALLAS, August 28, 2018 — Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications, today announced the initiation of its Phase 3 clinical trial of Vigil for individuals with Ewing’s sarcoma using product produced from Gradalis’ recently upgraded current Good Manufacturing Practice (cGMP) Carrollton facility. [Read more…]

Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal

August 24, 2018 By Cade Hildreth, Founder & President Leave a Comment

SAN CARLOS, Calif., Aug. 22, 2018 — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapy from BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the roll-in cohort reported. The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D. [Read more…]

FamiCord Acquires the Largest Stem Cell Bank in Portugal for $16.5M

August 21, 2018 By Cade Hildreth, Founder & President Leave a Comment

FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]

Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?

August 17, 2018 By Cade Hildreth, Founder & President Leave a Comment

Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord^®, is now in Phase 3 development for allogeneic bone marrow transplantation.

NiCord^®was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]

California Cryobank And CBR Combine To Create A Leading Life Sciences Platform

August 11, 2018 By Cade Hildreth, Founder & President Leave a Comment

LOS ANGELES, Aug. 6, 2018 — California Cryobank, the world’s leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment firm, from leading healthcare investors Longitude Capital and NovaQuest Capital.

In a separate transaction, GI Partners has also completed its acquisition of Cord Blood Registry (CBR), the world’s largest stem cell collection and storage company, from AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). [Read more…]